Page last updated: 2024-09-04

ezetimibe and niacin

ezetimibe has been researched along with niacin in 107 studies

Compound Research Comparison

Studies (ezetimibe)	Trials (ezetimibe)	Recent Studies (post-2010) (ezetimibe)	Studies (niacin)	Trials (niacin)	Recent Studies (post-2010) (niacin)
2,484	563	1,465	11,974	462	1,488

Protein Interaction Comparison

Protein	Taxonomy	niacin (IC50)
Cholesteryl ester transfer protein	Homo sapiens (human)	0.14
Cytochrome P450 2C9	Homo sapiens (human)	0.14
Hydroxycarboxylic acid receptor 2	Homo sapiens (human)	0.1726
Hydroxycarboxylic acid receptor 2	Mus musculus (house mouse)	0.14

Research

Studies (107)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	42 (39.25)	29.6817
2010's	60 (56.07)	24.3611
2020's	5 (4.67)	2.80

Authors

Authors	Studies
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Bruckert, E	1
Ballantyne, CM; Xydakis, AM	1
Brown, AS	1
Davidson, MH	1
Cottrell, DA; Falko, JM; Marshall, BJ	1
Davidson, MH; Toth, PP	1
Denke, MA	1
Charlotte, N; Sani, M	1
Ansell, BJ	2
Mosca, L	1
McKenney, JM	1
Ducobu, J	1
Balbisi, EA	1
Schulz, I	1
Patel, J	1
Cicero, AF; Derosa, G; Salvadeo, S	1
Backes, JM; Gibson, CA; Howard, PA	1
Balcerak, M; Broncel, M; Chojnowska-Jezierska, J	1
Bhardwaj, SS; Chalasani, N	1
Bouknight, P; Heffington, M; Mackler, L	1
Hostalek, U; Kassner, U; Steinhagen-Thiessen, E; Vogt, A	1
Brown, BG; Fazio, S; Guyton, JR; Polis, A; Tershakovec, AM; Tomassini, JE	1
Kaye, T	1
Robinson, JG	1
Guthrie, R	1
Hughes, S	1
Bulai Livideanu, C; Ferrières, J; Lamant, L; Maybon, P; Mazereeuw-Hautier, J; Paul, C; Periquet, B; Royer, M	1
Goldberg, AC; Hou, R	1
Avis, HJ; Hutten, BA; Kastelein, JJ; Vissers, MN; Wijburg, FA	1
Jones, PH	1
Blumenthal, RS; Michos, ED	1
Devine, PJ; Griffen, L; Miller, M; Stanek, EJ; Taylor, AJ; Turco, M; Villines, TC; Weissman, NJ	2
Bots, ML; Kastelein, JJ	1
Charland, SL; Malone, DC	1
Kole, LA	1
Parhofer, K	1
Mitka, M	1
Rosenson, RS	1
Adewale, AJ; Fazio, S; Guyton, JR; Polis, AB; Ryan, NW; Tershakovec, AM; Tomassini, JE	1
Dunn, FL	1
Halcox, JP; Lindsay, AC	1
Duivenvoorden, R; Kastelein, JJ; Vergeer, M	1
Roman, MJ	1
Weiss, SH	1
Ferrario, CM	1
Ahmed, MH	1
Phillips, W; Schaefer, S	1
Rizzoni, D; Rossi, GP	1
Drakopoulou, M; Skoumas, I; Stefanadis, C; Toutouzas, K	1
Gupta, A; Guyomard, V; Myint, PK; Rehman, HU; Zaman, MJ	1
Bangit, JR; Batsell, RR; Miraskar, RA; Reddy, KJ; Singh, M; Zaheer, MS	1
Olsson, AG	1
Lee, T	1
Jacobson, TA	1
Cutler, DL; Kim, KT; Kosoglou, T; Statkevich, P; Taggart, W; Triantafyllou, I; Xuan, F; Zhu, Y	1
Ballantyne, CM; Dong, JF; Kimball, KT; Lumsden, AB; Morrisett, JD; Nambi, V; Saunders, J; Virani, SS	1
Doggrell, SA	1
Bullano, MF; Chang, CL; Cziraky, MJ; Gandhi, SK; Kamat, SA	1
Elis, A; Stein, EA; Zhou, R	1
Sharma, M	1
Diep, F	1
Bandgar, TR; Faruqui, AA	1
Prasad, V; Vandross, A	1
Banach, M; Davidson, M; Mikhailidis, DP; Nicholls, SJ; Otocka-Kmiecik, A; Rysz, J	1
Critchley, WR; Shah, MK; Shaw, SM; Williams, SG; Yonan, N	1
Cabré, A; Masana, L; Plana, N	1
Abate, N; Montalto, G; Nikolic, D; Rizvi, AA; Rizzo, M; Sallam, HS	1
Ballantyne, CM; Brunner, G; Chen, C; Dong, JF; Hoogeveen, RC; Kougias, P; Kumar, A; Lin, PH; Lumsden, AB; Morrisett, JD; Murray, T; Nambi, V; Negi, SI; Sun, W; Taylor, A; Virani, SS; Yang, EY	1
Bajnok, L	1
Chelladurai, Y; Gudzune, KA; Monroe, AK; Ranasinghe, PD; Robinson, KA; Sharma, R	1
Jain, M; Zafrir, B	1
Brudi, P; Catapano, AL; Farnier, M; Foody, JM; Tershakovec, AM; Tomassini, JE; Toth, PP	1
Güleç, S; Özcan, ÖU	1
Sekhar, RV	1
Kramer, W	1
Knight, M; Sando, KR	1
Bittner, V; Deng, L; Farkouh, ME; Glasser, SP; Kent, ST; Muntner, P; Rosenson, RS; Taylor, B	1
Albers, JJ; Fleg, JL; Marcovina, SM; O'Brien, KD; Slee, A	1
Collins, PD; Sattar, N	1
Ashraf, TB; Ballantyne, CM; Cressman, MD; Gill, GG; Hunter, JA; Johnson-Levonas, AO; Kher, U; Mitchel, YB; Shah, S	1
Jaffa, FM; Johnson, E; Kalyani, RR; Shubrook, JH; Skolnik, N	1
Nozue, T	1
Agrawal, S; Fornoni, A; Smoyer, WE; Zaritsky, JJ	1
Athyros, VG; Giannoukas, AD; Katsiki, N; Mikhailidis, DP	1
Hsiung, JT; Kleine, CE; Moradi, H; Park, C; Soohoo, M; Streja, DA; Streja, E	1
Fichtenbaum, CJ; Gebhardt, A	1
Bangalore, S; Chaudhry, R; Costa, SP; Lyubarova, R; Mathew, RO; Rosenson, RS; Sidhu, MS	1
Chen, Q; Guo, Q; He, Z; Li, H; Lu, L; Sun, R; Wang, J; Xu, X; Zhang, Y	1
Abushanab, D; Ademi, Z; Al-Badriyeh, D; Bailey, C; Jaam, M; Liew, D; Marquina, C	1
Huang, T; Jiao, L; Li, L; Luo, J; Ma, Y; Wang, J; Wang, T; Wang, X; Xu, R; Yang, B; Yang, H; Yang, R; Yang, Y; Zhang, X; Zhang, Y	1
Allan, GM; Braschi, É; Dugré, N; Falk, J; Froentjes, L; Garrison, SR; Kirkwood, JEM; Kolber, MR; Korownyk, CS; Lindblad, AJ; McCormack, JP; Moe, SS; Paige, A; Perry, D; Potter, J; Thomas, BS; Ton, J; Weresch, J; Young, J	1

Reviews

51 review(s) available for ezetimibe and niacin

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016
New advances in lipid-modifying therapies for reducing cardiovascular risk. Cardiology, 2002, Volume: 97, Issue:2 Topics: Acetamides; Acetates; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Niacin; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Sulfonic Acids	2002
Combination therapy for combined dyslipidemia. The American journal of cardiology, 2002, Nov-20, Volume: 90, Issue:10B Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Fatty Acids, Omega-3; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemia, Familial Combined; Hyperlipidemias; Hypolipidemic Agents; Niacin; Practice Guidelines as Topic; Triglycerides	2002
Therapeutic approaches to dyslipidemia in diabetes mellitus and metabolic syndrome. Current opinion in cardiology, 2003, Volume: 18, Issue:4 Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Ezetimibe; Fenofibrate; Fish Oils; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertriglyceridemia; Hypolipidemic Agents; Metabolic Syndrome; Niacin; Particle Size	2003
Combination therapy in the management of complex dyslipidemias. Current opinion in lipidology, 2004, Volume: 15, Issue:4 Topics: Algorithms; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipoproteins; Niacin	2004
Coadministration of multidrug therapy to achieve lipid goals. The Journal of the American Osteopathic Association, 2004, Volume: 104, Issue:9 Suppl 7 Topics: Anticholesteremic Agents; Azetidines; Clofibric Acid; Coronary Disease; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipids; Male; Middle Aged; Niacin; Risk Factors	2004
Rationale for combination therapy with statin drugs in the treatment of dyslipidemia. Current atherosclerosis reports, 2005, Volume: 7, Issue:1 Topics: Anion Exchange Resins; Antihypertensive Agents; Azetidines; Benzenesulfonates; Clofibric Acid; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypoglycemic Agents; Hypolipidemic Agents; Niacin; Quinolines	2005
Drugs for lipids. Treatment guidelines from the Medical Letter, 2005, Volume: 3, Issue:31 Topics: Anticholesteremic Agents; Apolipoproteins; Azetidines; Bile Acids and Salts; Cholesterol; Cholesterol, LDL; Clofibric Acid; Drug Interactions; Ezetimibe; Female; Fish Oils; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Niacin; Pregnancy; Triglycerides	2005
Management of dyslipidemia in women in the post-hormone therapy era. Journal of general internal medicine, 2005, Volume: 20, Issue:3 Topics: Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, HDL; Clofibric Acid; Dietary Supplements; Disease Management; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Life Style; Niacin; Practice Guidelines as Topic; Triglycerides	2005
Pharmacologic options for aggressive low-density lipoprotein cholesterol lowering: benefits versus risks. The American journal of cardiology, 2005, Aug-22, Volume: 96, Issue:4A Topics: Allylamine; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Clinical Trials as Topic; Colesevelam Hydrochloride; Coronary Artery Disease; Drug Therapy, Combination; Ezetimibe; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Muscular Diseases; Niacin; Pyrimidines; Pyrroles; Rhabdomyolysis; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome	2005
Management of hyperlipidemia: new LDL-C targets for persons at high-risk for cardiovascular events. Medical science monitor : international medical journal of experimental and clinical research, 2006, Volume: 12, Issue:2 Topics: Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Cholestyramine Resin; Clofibric Acid; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Life Style; Niacin; Risk Factors	2006
[Treatment of dyslipidemia: how and when to combine lipid lowering drugs]. Arquivos brasileiros de endocrinologia e metabologia, 2006, Volume: 50, Issue:2 Topics: Anticholesteremic Agents; Azetidines; Cholesterol, HDL; Clofibric Acid; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipids; Lipoproteins, HDL; Lipoproteins, LDL; Niacin	2006
Dyslipidaemia in diabetes. Clinical evidence, 2006, Issue:15 Topics: Azetidines; Bezafibrate; Diabetes Complications; Diabetic Angiopathies; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Fish Oils; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Niacin	2006
Prospects for the development of novel anti-hyperlipidemic drugs. Current opinion in investigational drugs (London, England : 2000), 2006, Volume: 7, Issue:9 Topics: Animals; Azetidines; Cardiovascular Diseases; Carrier Proteins; Cholesterol Ester Transfer Proteins; Ezetimibe; Glycoproteins; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Microsomes; Niacin; Sterol O-Acyltransferase	2006
Optimal lipid modification: the rationale for combination therapy. Vascular health and risk management, 2005, Volume: 1, Issue:4 Topics: Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Clinical Trials as Topic; Clofibric Acid; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Niacin; Patient Compliance; Patient Selection; Practice Guidelines as Topic; Research Design; Treatment Outcome	2005
[Influence of combined, hypolipemic therapy on lipids and non-lipid atherosclerosis risk factors]. Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 2007, Volume: 22, Issue:127 Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Drug Therapy, Combination; Ezetimibe; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Niacin; Risk Factors; Simvastatin	2007
Lipid-lowering agents that cause drug-induced hepatotoxicity. Clinics in liver disease, 2007, Volume: 11, Issue:3 Topics: Azetidines; Chemical and Drug Induced Liver Injury; Cholesterol Ester Transfer Proteins; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Niacin	2007
FPIN's clinical inquiries. Best alternatives to statins for treating hyperlipidemia. American family physician, 2007, Oct-01, Volume: 76, Issue:7 Topics: Anion Exchange Resins; Azetidines; Clofibric Acid; Evidence-Based Medicine; Ezetimibe; Fatty Acids, Omega-3; Garlic; Humans; Hyperlipidemias; Hypolipidemic Agents; Niacin; Phytotherapy; Plant Preparations	2007
Prolonged-release nicotinic acid for the management of dyslipidemia: an update including results from the NAUTILUS study. Vascular health and risk management, 2007, Volume: 3, Issue:4 Topics: Atorvastatin; Azetidines; Cholesterol, HDL; Delayed-Action Preparations; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Fluorobenzenes; Heptanoic Acids; Humans; Hypolipidemic Agents; Niacin; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2007
LDL reduction: how low should we go and is it safe? Current cardiology reports, 2008, Volume: 10, Issue:6 Topics: Allylamine; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Colesevelam Hydrochloride; Coronary Artery Disease; Disease Progression; Drug Therapy, Combination; Ezetimibe; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Muscular Diseases; Niacin; Risk Factors; Stroke	2008
A review of trials evaluating nonstatin lipid-lowering therapies. Current atherosclerosis reports, 2009, Volume: 11, Issue:1 Topics: Anticholesteremic Agents; Azetidines; Clinical Trials as Topic; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Niacin	2009
Lowering low-density lipoprotein cholesterol: statins, ezetimibe, bile acid sequestrants, and combinations: comparative efficacy and safety. Endocrinology and metabolism clinics of North America, 2009, Volume: 38, Issue:1 Topics: Animals; Anticholesteremic Agents; Azetidines; Bile Acids and Salts; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins, LDL; Niacin	2009
The use of lipid-lowering drug therapy in children and adolescents. Current opinion in investigational drugs (London, England : 2000), 2009, Volume: 10, Issue:3 Topics: Adolescent; Atherosclerosis; Azetidines; Bile Acids and Salts; Cardiovascular Diseases; Child; Cholesterol; Clofibric Acid; Disease Progression; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Ion Exchange Resins; Niacin; Practice Guidelines as Topic; Treatment Outcome	2009
Prediction of cardiovascular event risk reduction from lipid changes associated with high potency dyslipidemia therapy. Current medical research and opinion, 2010, Volume: 26, Issue:2 Topics: Algorithms; Azetidines; Cardiovascular Diseases; Dyslipidemias; Ezetimibe; Female; Humans; Hypolipidemic Agents; Lipids; Lovastatin; Male; Middle Aged; Niacin; Prognosis; Randomized Controlled Trials as Topic; Risk Reduction Behavior; Simvastatin	2010
Management of dyslipidemia in people with type 2 diabetes mellitus. Reviews in endocrine & metabolic disorders, 2010, Volume: 11, Issue:1 Topics: Azetidines; Cholesterol, LDL; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dyslipidemias; Ezetimibe; Fenofibrate; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Male; Middle Aged; Niacin; Patient Education as Topic; Triglycerides	2010
Advancing therapy for hypercholesterolemia. Expert opinion on pharmacotherapy, 2010, Volume: 11, Issue:10 Topics: Azetidines; Bile Acids and Salts; Carrier Proteins; Cholesterol; Cholesterol Ester Transfer Proteins; Cholesterol, LDL; Ezetimibe; Farnesyl-Diphosphate Farnesyltransferase; Fatty Acids, Omega-3; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Intestinal Absorption; Niacin	2010
Systematic review on evidence of the effectiveness of cholesterol-lowering drugs. Advances in therapy, 2010, Volume: 27, Issue:6 Topics: Anticholesteremic Agents; Azetidines; Cholestyramine Resin; Coronary Disease; Drug Therapy, Combination; Evidence-Based Practice; Ezetimibe; Fatty Acids, Omega-3; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Niacin; Patient Selection; Phytosterols; Practice Guidelines as Topic; Primary Prevention; Risk Assessment; Risk Factors; Risk Reduction Behavior; Secondary Prevention; Treatment Outcome	2010
'Trig-onometry': non-high-density lipoprotein cholesterol as a therapeutic target in dyslipidaemia. International journal of clinical practice, 2011, Volume: 65, Issue:1 Topics: Adult; Azetidines; Cardiovascular Diseases; Cholesterol, HDL; Dyslipidemias; Ezetimibe; Fatty Acids, Omega-3; Female; Fibric Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Middle Aged; Niacin; Practice Guidelines as Topic; Risk Factors; Young Adult	2011
Lowering LDL cholesterol with margarine containing plant stanol/sterol esters: is it still relevant in 2011? Complementary therapies in medicine, 2011, Volume: 19, Issue:1 Topics: Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus; Ezetimibe; Fibric Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipoproteinemia Type II; Intestinal Diseases; Lipid Metabolism, Inborn Errors; Margarine; Micronutrients; Niacin; Phytosterols; Sitosterols; Triglycerides	2011
Combination therapy for dyslipidemia. Current opinion in cardiology, 2011, Volume: 26, Issue:5 Topics: Anticholesteremic Agents; Azetidines; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Fibric Acids; Humans; Niacin	2011
Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease? Progress in lipid research, 2012, Volume: 51, Issue:4 Topics: Animals; Apolipoproteins; Azetidines; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Ezetimibe; Fibric Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Niacin; Peroxidase; Thiazolidinediones	2012
Second line options for hyperlipidemia management after cardiac transplantation. Cardiovascular therapeutics, 2013, Volume: 31, Issue:3 Topics: Azetidines; Bezafibrate; Diet; Exercise; Ezetimibe; Fish Oils; Heart Transplantation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Niacin	2013
Adipokines and lipoproteins: modulation by antihyperglycemic and hypolipidemic agents. Metabolic syndrome and related disorders, 2014, Volume: 12, Issue:1 Topics: Adipokines; Adipose Tissue; Animals; Anti-Obesity Agents; Azetidines; Ezetimibe; Fibric Acids; Glucose; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Hypolipidemic Agents; Incretins; Insulin; Insulin Resistance; Lipids; Lipoproteins; Metabolic Syndrome; Metformin; Niacin; Thiazolidinediones	2014
[HDL, or non-HDL: that is the question. Possibilities of pharmacological treatment in residual dyslipidaemia]. Orvosi hetilap, 2014, Jan-12, Volume: 155, Issue:2 Topics: Anticholesteremic Agents; Azetidines; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Dyslipidemias; Ezetimibe; Fibric Acids; Fish Oils; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Niacin; Proprotein Convertase 9; Proprotein Convertases; Serine Endopeptidases	2014
Effectiveness of combination therapy with statin and another lipid-modifying agent compared with intensified statin monotherapy: a systematic review. Annals of internal medicine, 2014, Apr-01, Volume: 160, Issue:7 Topics: Anticholesteremic Agents; Azetidines; Bile Acids and Salts; Cholesterol, LDL; Coronary Artery Disease; Drug Therapy, Combination; Ezetimibe; Fatty Acids, Omega-3; Fibric Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Medication Adherence; Niacin; Randomized Controlled Trials as Topic; Risk Factors; Treatment Outcome	2014
Lipid-lowering therapies, glucose control and incident diabetes: evidence, mechanisms and clinical implications. Cardiovascular drugs and therapy, 2014, Volume: 28, Issue:4 Topics: Animals; Azetidines; Bile Acids and Salts; Blood Glucose; Cholesterol Ester Transfer Proteins; Diabetes Mellitus; Ezetimibe; Fibric Acids; Fish Oils; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipid Metabolism; Niacin	2014
Combination therapy in dyslipidemia: where are we now? Atherosclerosis, 2014, Volume: 237, Issue:1 Topics: Azetidines; Bile Acids and Salts; Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; Clinical Trials as Topic; Dyslipidemias; Ezetimibe; Female; Fibric Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Lipids; Male; Niacin; Patient Compliance; Proprotein Convertase 9; Proprotein Convertases; Serine Endopeptidases; Treatment Outcome	2014
[Heterozygous familial hypercholesterolemia]. Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir, 2014, Volume: 42 Suppl 2 Topics: Azetidines; Early Diagnosis; Ezetimibe; Genetic Predisposition to Disease; Genetic Testing; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Niacin	2014
Treatment of dyslipidemia in HIV. Current atherosclerosis reports, 2015, Volume: 17, Issue:4 Topics: Anti-HIV Agents; Anticholesteremic Agents; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Diet Therapy; Dyslipidemias; Exercise Therapy; Ezetimibe; Fatty Acids, Nonesterified; Fatty Acids, Omega-3; Fibric Acids; Glutathione; Growth Hormone-Releasing Hormone; HIV Infections; Human Growth Hormone; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leptin; Niacin; Pyrazines; Thiazolidinediones; Triglycerides	2015
Antilipidemic Drug Therapy Today and in the Future. Handbook of experimental pharmacology, 2016, Volume: 233 Topics: Cholesterol, HDL; Cholesterol, LDL; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Niacin; Triglycerides	2016
Nonstatin therapies for management of dyslipidemia: a review. Clinical therapeutics, 2015, Oct-01, Volume: 37, Issue:10 Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, LDL; Clofibrate; Disease Management; Dyslipidemias; Ezetimibe; Fatty Acids, Omega-3; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Niacin; Proprotein Convertases; Risk Factors; Saccharomyces cerevisiae Proteins; Triglycerides; United States	2015
Glycaemic Effects of Non-statin Lipid-Lowering Therapies. Current cardiology reports, 2016, Volume: 18, Issue:12 Topics: Anticholesteremic Agents; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Ezetimibe; Fibric Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Lipid Metabolism; Meta-Analysis as Topic; Niacin; PCSK9 Inhibitors; Randomized Controlled Trials as Topic; Treatment Outcome	2016
Lipid Lowering Therapy and Circulating PCSK9 Concentration. Journal of atherosclerosis and thrombosis, 2017, Sep-01, Volume: 24, Issue:9 Topics: Antibodies, Monoclonal; Biomarkers; Cholesterol, LDL; Ezetimibe; Fibric Acids; Gene Silencing; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Lipid Metabolism; Niacin; PCSK9 Inhibitors; Proprotein Convertase 9	2017
Dyslipidaemia in nephrotic syndrome: mechanisms and treatment. Nature reviews. Nephrology, 2018, Volume: 14, Issue:1 Topics: Anticholesteremic Agents; Cholesterol; Cholesterol, HDL; Cholesterol, VLDL; Dyslipidemias; Ezetimibe; Fibric Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipase; Lipoprotein Lipase; Lipoproteins; Nephrotic Syndrome; Niacin; Proprotein Convertase 9; Triglycerides	2018
Lipid-lowering treatment in peripheral artery disease. Current opinion in pharmacology, 2018, Volume: 39 Topics: Animals; Cholesterol Ester Transfer Proteins; Ezetimibe; Fibric Acids; Humans; Hypolipidemic Agents; Niacin; PCSK9 Inhibitors; Peripheral Arterial Disease	2018
Precision Medicine and Personalized Management of Lipoprotein and Lipid Disorders in Chronic and End-Stage Kidney Disease. Seminars in nephrology, 2018, Volume: 38, Issue:4 Topics: Anticholesteremic Agents; Cardiovascular Diseases; Dyslipidemias; Ezetimibe; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Kidney Failure, Chronic; Muscular Diseases; Niacin; PCSK9 Inhibitors; Pharmacogenomic Variants; Practice Guidelines as Topic; Precision Medicine; Renal Dialysis; Renal Insufficiency, Chronic	2018
Current pharmacotherapy for the treatment of dyslipidemia associated with HIV infection. Expert opinion on pharmacotherapy, 2019, Volume: 20, Issue:14 Topics: Anti-Retroviral Agents; Drug Interactions; Dyslipidemias; Ezetimibe; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Niacin; Risk Assessment	2019
Concepts and Controversies: Lipid Management in Patients with Chronic Kidney Disease. Cardiovascular drugs and therapy, 2021, Volume: 35, Issue:3 Topics: Atherosclerosis; Ezetimibe; Fibric Acids; Glomerular Filtration Rate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lipids; Niacin; Patient Acuity; PCSK9 Inhibitors; Practice Guidelines as Topic; Proprotein Convertase 9; Randomized Controlled Trials as Topic; Renal Dialysis; Renal Insufficiency, Chronic; Risk Factors	2021
The comparative impact among different intensive statins and combination therapies with niacin/ezetimibe on carotid intima-media thickness: a systematic review, traditional meta-analysis, and network meta-analysis of randomized controlled trials. European journal of clinical pharmacology, 2021, Volume: 77, Issue:8 Topics: Carotid Intima-Media Thickness; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Network Meta-Analysis; Niacin; Randomized Controlled Trials as Topic	2021
A Systematic Review of Cost-Effectiveness of Non-Statin Lipid-Lowering Drugs for Primary and Secondary Prevention of Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus. Current problems in cardiology, 2023, Volume: 48, Issue:8 Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Ezetimibe; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Niacin; Proprotein Convertases; Secondary Prevention; Subtilisins	2023
Lipid-lowering therapies for cardiovascular disease prevention and management in primary care: PEER umbrella systematic review of systematic reviews. Canadian family physician Medecin de famille canadien, 2023, Volume: 69, Issue:10 Topics: Anticholesteremic Agents; Cardiovascular Diseases; Ezetimibe; Fibric Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Niacin; PCSK9 Inhibitors; Primary Health Care; Proprotein Convertase 9; Systematic Reviews as Topic	2023

Trials

11 trial(s) available for ezetimibe and niacin

Article	Year
Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia. Journal of the American College of Cardiology, 2008, Apr-22, Volume: 51, Issue:16 Topics: Adolescent; Adult; Anticholesteremic Agents; Apolipoproteins; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Delayed-Action Preparations; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lipids; Male; Middle Aged; Niacin; Simvastatin	2008
Extended-release niacin or ezetimibe and carotid intima-media thickness. The New England journal of medicine, 2009, Nov-26, Volume: 361, Issue:22 Topics: Aged; Anticholesteremic Agents; Azetidines; Carotid Arteries; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Delayed-Action Preparations; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Male; Middle Aged; Niacin; Risk Factors; Single-Blind Method; Triglycerides; Tunica Intima; Tunica Media; Ultrasonography	2009
Long-term safety and efficacy of triple combination ezetimibe/simvastatin plus extended-release niacin in patients with hyperlipidemia. The American journal of cardiology, 2010, Feb-15, Volume: 105, Issue:4 Topics: Adolescent; Adult; Aged; Azetidines; Biomarkers; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Delayed-Action Preparations; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Follow-Up Studies; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins; Male; Middle Aged; Niacin; Severity of Illness Index; Simvastatin; Tennessee; Time Factors; Treatment Outcome; Vitamin B Complex	2010
The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration. Journal of the American College of Cardiology, 2010, Jun-15, Volume: 55, Issue:24 Topics: Aged; Anticholesteremic Agents; Atherosclerosis; Azetidines; Carotid Artery, Common; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Dose-Response Relationship, Drug; Ezetimibe; Female; Follow-Up Studies; Humans; Male; Medication Adherence; Niacin; Single-Blind Method; Time Factors; Treatment Outcome; Tunica Intima; Ultrasonography	2010
Assessment of potential pharmacokinetic interactions of ezetimibe/simvastatin and extended-release niacin tablets in healthy subjects. European journal of clinical pharmacology, 2011, Volume: 67, Issue:5 Topics: Adult; Anticholesteremic Agents; Azetidines; Cross-Over Studies; Delayed-Action Preparations; Drug Interactions; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hypolipidemic Agents; Lipids; Male; Niacin; Nicotinic Acids; Simvastatin; Tablets	2011
Variability and persistence of aspirin response in lower extremity peripheral arterial disease patients. Journal of vascular surgery, 2011, Volume: 53, Issue:3 Topics: Adenosine Diphosphate; Adult; Aged; Aged, 80 and over; Angioplasty, Balloon; Arachidonic Acid; Aspirin; Azetidines; Double-Blind Method; Drug Resistance; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lower Extremity; Male; Middle Aged; Niacin; Peripheral Arterial Disease; Placebo Effect; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Predictive Value of Tests; Stents; Time Factors; Treatment Outcome	2011
The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol Rationale and study design. The Atherothro American heart journal, 2011, Volume: 161, Issue:3 Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Ezetimibe; Humans; Hypolipidemic Agents; Metabolic Syndrome; Niacin; Research Design; Simvastatin; Treatment Outcome	2011
The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol: baseline characteristics of study partici American heart journal, 2011, Volume: 161, Issue:3 Topics: Aged; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, HDL; Coronary Artery Disease; Delayed-Action Preparations; Drug Therapy, Combination; Endpoint Determination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Middle Aged; Niacin; Simvastatin; Triglycerides	2011
The Effect of Lipid Modification on Peripheral Artery Disease after Endovascular Intervention Trial (ELIMIT). Atherosclerosis, 2013, Volume: 231, Issue:2 Topics: Aged; Azetidines; Cholesterol; Double-Blind Method; Endothelium, Vascular; Ezetimibe; Female; Femoral Artery; Humans; Lipids; Lipoproteins; Magnetic Resonance Imaging; Male; Middle Aged; Niacin; Peripheral Arterial Disease; Simvastatin	2013
Relationship of baseline HDL subclasses, small dense LDL and LDL triglyceride to cardiovascular events in the AIM-HIGH clinical trial. Atherosclerosis, 2016, Volume: 251 Topics: Aged; Anticholesteremic Agents; Cardiovascular Diseases; Cardiovascular System; Cholesterol, HDL; Cohort Studies; Coronary Artery Disease; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Myocardial Infarction; Niacin; Proportional Hazards Models; Simvastatin; Treatment Outcome; Triglycerides	2016
Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients with Hypercholesterolemia or Low High-Density Lipoprotein Cholesterol. The American journal of cardiology, 2017, Feb-01, Volume: 119, Issue:3 Topics: Aged; Anticholesteremic Agents; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Fibric Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Niacin; Oxazolidinones; Treatment Outcome	2017

Other Studies

45 other study(ies) available for ezetimibe and niacin

Article	Year
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. Chemical research in toxicology, 2010, Volume: 23, Issue:1 Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship	2010
Use of combination therapy for dyslipidemia: a lipid clinic approach. The American journal of cardiology, 2002, Nov-20, Volume: 90, Issue:10B Topics: Anticholesteremic Agents; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Niacin; Triglycerides	2002
Combination therapy for dyslipidemia: safety and regulatory considerations. The American journal of cardiology, 2002, Nov-20, Volume: 90, Issue:10B Topics: Algorithms; Anticholesteremic Agents; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Niacin; Safety	2002
Three new drugs for hyperlipidemia. The Medical letter on drugs and therapeutics, 2003, Mar-03, Volume: 45, Issue:1151 Topics: Azetidines; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Combinations; Ezetimibe; Humans; Hyperlipidemias; Hypolipidemic Agents; Intestinal Absorption; Lovastatin; Muscular Diseases; Niacin	2003
Three new drugs for hyperlipidemia. Connecticut medicine, 2003, Volume: 67, Issue:5 Topics: Azetidines; Clinical Trials as Topic; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Combinations; Ezetimibe; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Niacin	2003
How doubling up drugs saves lives. Why doctors increasingly deploy an array of medications all at once. Heart advisor, 2004, Volume: 7, Issue:6 Topics: Anticholesteremic Agents; Azetidines; Drug Combinations; Drug Interactions; Drug Therapy, Combination; Ezetimibe; Gemfibrozil; Humans; Niacin	2004
Lipid-lowering drugs. Nursing older people, 2004, Volume: 16, Issue:9 Topics: Anticholesteremic Agents; Azetidines; Cholestyramine Resin; Coronary Disease; Ezetimibe; Fatty Acids, Omega-3; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Niacin; Risk Factors; Treatment Outcome	2004
[Innovative therapies in metabolic diseases: ezetimibe (Ezétrol), nicotinic acid (Niaspan), acids omega-3 (Omacor), rimonabant (Acomplia)]. Revue medicale de Bruxelles, 2005, Volume: 26, Issue:4 Topics: Anticholesteremic Agents; Azetidines; Ezetimibe; Fatty Acids, Omega-3; Humans; Hyperlipidemias; Hypolipidemic Agents; Metabolic Syndrome; Niacin; Piperidines; Pyrazoles; Rimonabant	2005
Lower cholesterol without statins. Options are available. Mayo Clinic health letter (English ed.), 2006, Volume: 24, Issue:5 Topics: Allylamine; Azetidines; Cholesterol, LDL; Cholinergic Antagonists; Colesevelam Hydrochloride; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Niacin; Phytosterols	2006
Help for your cholesterol when statins won't do. If you are one of the many, but also one of the few... Harvard men's health watch, 2005, Volume: 9, Issue:8 Topics: Anticholesteremic Agents; Azetidines; Clofibric Acid; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Life Style; Male; Niacin	2005
Simvastatin with or without ezetimibe in familial hypercholesterolemia. The New England journal of medicine, 2008, Jul-31, Volume: 359, Issue:5 Topics: Anticholesteremic Agents; Azetidines; Clofibric Acid; Drug Therapy, Combination; Ezetimibe; Humans; Hyperlipoproteinemia Type II; Niacin; Simvastatin	2008
Should we treat all primary prevention patients with statins? Current atherosclerosis reports, 2009, Volume: 11, Issue:1 Topics: Azetidines; Bile Acids and Salts; Cardiovascular Diseases; Cholesterol; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Niacin; Primary Prevention; Triglycerides; Vitamin B Complex	2009
On the road to better dyslipidemia outcomes. The Nurse practitioner, 2009, Volume: 34, Issue:2 Topics: Azetidines; Cardiovascular Diseases; Clofibric Acid; Dyslipidemias; Ezetimibe; Fish Oils; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Life Style; Lipid Metabolism; Metabolic Syndrome; Niacin; Physical Examination; Risk Assessment; Risk Factors; Vitamin B Complex	2009
[Orange skin and xanthomas associated with lycopenaemia in a setting of type III dyslipoproteinemia]. Annales de dermatologie et de venereologie, 2009, Volume: 136, Issue:1 Topics: Azetidines; Carotenoids; Ezetimibe; Female; Humans; Hyperlipoproteinemia Type III; Hypolipidemic Agents; Lycopene; Middle Aged; Niacin; Pigmentation Disorders; Skin Diseases; Xanthomatosis	2009
Achieving cholesterol goals. Current and future drug therapies. Postgraduate medicine, 2003, Volume: 114, Issue:2 Suppl Topics: Aged; Anticholesteremic Agents; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Dyslipidemias; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Niacin	2003
The HALTS trial--halting atherosclerosis or halted too early? The New England journal of medicine, 2009, Nov-26, Volume: 361, Issue:22 Topics: Anticholesteremic Agents; Azetidines; Carotid Arteries; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Delayed-Action Preparations; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Niacin; Research Design; Tunica Intima; Tunica Media	2009
Statin therapy with ezetimibe or niacin in high-risk patients. The New England journal of medicine, 2009, Nov-26, Volume: 361, Issue:22 Topics: Anticholesteremic Agents; Azetidines; Carotid Arteries; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Delayed-Action Preparations; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Niacin; Research Design; Tunica Intima; Tunica Media	2009
Lipid disorders. JAAPA : official journal of the American Academy of Physician Assistants, 2009, Volume: 22, Issue:11 Topics: Anticholesteremic Agents; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Coronary Disease; Ezetimibe; Humans; Hyperlipidemias; Hypolipidemic Agents; Niacin; Vitamin B Complex	2009
[Statin plus niacin or ezetimibe? What combination for which patients?]. MMW Fortschritte der Medizin, 2009, Dec-03, Volume: 151, Issue:49-50 Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Carotid Artery Diseases; Coronary Disease; Drug Therapy, Combination; Ezetimibe; Humans; Hypolipidemic Agents; Niacin; Prospective Studies; Randomized Controlled Trials as Topic; Risk Factors; Time Factors	2009
Cholesterol drug lowers LDL-C levels but again fails to show clinical benefit. JAMA, 2010, Jan-20, Volume: 303, Issue:3 Topics: Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Carotid Arteries; Cholesterol, LDL; Clinical Trials as Topic; Drug Approval; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Niacin; Practice Patterns, Physicians'; Risk Factors; Simvastatin; Treatment Outcome; Ultrasonography; United States; United States Food and Drug Administration	2010
Functional assessment of HDL: Moving beyond static measures for risk assessment. Cardiovascular drugs and therapy, 2010, Volume: 24, Issue:1 Topics: Amides; Animals; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Esters; Ezetimibe; Glucose; Humans; Insulin; Lipase; Lipoproteins, HDL; Niacin; Quinolines; Risk Assessment; Risk Factors; Sulfhydryl Compounds	2010
Niacin compared with ezetimibe. The New England journal of medicine, 2010, Mar-18, Volume: 362, Issue:11 Topics: Anticholesteremic Agents; Azetidines; Blood Pressure; Carotid Arteries; Coronary Disease; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Niacin; Vasodilator Agents	2010
Niacin compared with ezetimibe. The New England journal of medicine, 2010, Mar-18, Volume: 362, Issue:11 Topics: Anticholesteremic Agents; Azetidines; Carotid Arteries; Cholesterol, LDL; Coronary Disease; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Niacin; Tunica Intima; Tunica Media	2010
Niacin compared with ezetimibe. The New England journal of medicine, 2010, Mar-18, Volume: 362, Issue:11 Topics: Anticholesteremic Agents; Azetidines; Carotid Arteries; Coronary Disease; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Niacin; Tunica Intima; Tunica Media	2010
Niacin compared with ezetimibe. The New England journal of medicine, 2010, Mar-18, Volume: 362, Issue:11 Topics: Anticholesteremic Agents; Azetidines; Blood Glucose; Carotid Arteries; Coronary Disease; Diabetes Mellitus; Drug Therapy, Combination; Ezetimibe; Humans; Niacin; Patient Dropouts; Research Design	2010
I have had trouble controlling my cholesterol with a statin alone. Should I consider prescription niacin? The Johns Hopkins medical letter health after 50, 2010, Volume: 21, Issue:12 Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Coronary Disease; Drug Therapy, Combination; Ezetimibe; Health Knowledge, Attitudes, Practice; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Middle Aged; Niacin	2010
ARBITER 6-HALTS. Does it have the power to settle all matters? Therapeutic advances in cardiovascular disease, 2010, Volume: 4, Issue:2 Topics: Adult; Anticholesteremic Agents; Atherosclerosis; Azetidines; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Niacin; Randomized Controlled Trials as Topic; Risk Factors	2010
Ezetimibe and recent clinical trials: a look on the bright side. Expert opinion on drug safety, 2010, Volume: 9, Issue:4 Topics: Anticholesteremic Agents; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Delayed-Action Preparations; Drug Therapy, Combination; Ezetimibe; Humans; Hypercholesterolemia; Niacin; Placebos; Randomized Controlled Trials as Topic; Simvastatin; Treatment Outcome; Triglycerides	2010
LDL = 5: Virtues and dangers of multidrug therapy of low-density lipoprotein cholesterol. Preventive cardiology, 2010,Spring, Volume: 13, Issue:2 Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Liver; Male; Middle Aged; Niacin	2010
Therapy: raising HDL cholesterol levels: a flight of Icarus? Nature reviews. Endocrinology, 2010, Volume: 6, Issue:5 Topics: Atherosclerosis; Azetidines; Carotid Arteries; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Ezetimibe; Humans; Niacin; Quinolines	2010
Lipoprotein-associated phospholipase A2 mass is significantly reduced in dyslipidemic patients treated with lifestyle modification and combination lipid-modifying drug therapy. Preventive cardiology, 2010,Summer, Volume: 13, Issue:3 Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Allylamine; Anticholesteremic Agents; Azetidines; Biomarkers; Cholesterol, LDL; Colesevelam Hydrochloride; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Fatty Acids, Omega-3; Female; Humans; Inflammation; Life Style; Male; Middle Aged; Niacin; Regression Analysis; Retrospective Studies; Risk Factors; Simvastatin; Statistics as Topic; Vitamin B Complex	2010
HDL and LDL as therapeutic targets for cardiovascular disease prevention: the possible role of niacin. Nutrition, metabolism, and cardiovascular diseases : NMCD, 2010, Volume: 20, Issue:8 Topics: Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Ezetimibe; Humans; Niacin	2010
Ask the doctor. I have tried all of the statin drugs to lower my cholesterol, but each one has caused severe muscle pain. Are there any non-statin medications I could try using to lower my cholesterol? Harvard heart letter : from Harvard Medical School, 2010, Volume: 20, Issue:12 Topics: Allylamine; Azetidines; Colesevelam Hydrochloride; Diet, Mediterranean; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Muscular Diseases; Niacin; Pain; Sitosterols	2010
Adherence to single-pill combination versus multiple-pill combination lipid-modifying therapy among patients with mixed dyslipidemia in a managed care population. Current medical research and opinion, 2011, Volume: 27, Issue:5 Topics: Aged; Anticholesteremic Agents; Azetidines; Databases, Factual; Dyslipidemias; Ezetimibe; Female; Follow-Up Studies; Humans; Lovastatin; Male; Middle Aged; Niacin; Patient Compliance; Retrospective Studies; Simvastatin; Time Factors	2011
Effect of lipid-lowering treatment on natural history of heterozygous familial hypercholesterolemia in past three decades. The American journal of cardiology, 2011, Jul-15, Volume: 108, Issue:2 Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Child; Child, Preschool; Cholesterol; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Female; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Middle Aged; Myocardial Revascularization; Niacin; Ohio; Pyrimidines; Registries; Rosuvastatin Calcium; Sulfonamides; Vitamin B Complex; Young Adult	2011
Trial clouds use of niacin with a statin. Harvard heart letter : from Harvard Medical School, 2011, Volume: 21, Issue:12 Topics: Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, HDL; Clinical Trials as Topic; Coronary Artery Disease; Delayed-Action Preparations; Drug Therapy, Combination; Endpoint Determination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Niacin; Simvastatin; Treatment Failure	2011
Cholesterol conundrum. Scientific American, 2011, Volume: 305, Issue:5 Topics: Azetidines; Cholesterol, HDL; Cholesterol, LDL; Ezetimibe; Heart Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Niacin; Risk Factors; Stroke	2011
Managing dyslipidaemia: evolving role of combination therapy. Journal of the Indian Medical Association, 2011, Volume: 109, Issue:8 Topics: Atorvastatin; Azetidines; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Fenofibrate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipoproteins, HDL; Lipoproteins, LDL; Niacin; Pyrroles	2011
Cardiovascular primary prevention: how high should we set the bar? Archives of internal medicine, 2012, Apr-23, Volume: 172, Issue:8 Topics: Anticholesteremic Agents; Azetidines; Biomarkers; Cardiovascular Diseases; Cholesterol, LDL; Cost-Benefit Analysis; Drug Industry; Evidence-Based Medicine; Ezetimibe; Fenofibrate; Health Care Costs; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Mass Screening; Neoplasms; Niacin; Primary Prevention; Randomized Controlled Trials as Topic; Simvastatin	2012
HPS2-THRIVE results: bad for niacin/laropiprant, good for ezetimibe? Atherosclerosis, 2013, Volume: 229, Issue:2 Topics: Adaptor Protein Complex 3; Adaptor Protein Complex beta Subunits; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Ezetimibe; Humans; Hypolipidemic Agents; Indoles; Niacin; Simvastatin	2013
Drugs for lipids. Treatment guidelines from the Medical Letter, 2014, Volume: 12, Issue:137 Topics: Animals; Azetidines; Cholesterol; Drug Interactions; Drug Therapy, Combination; Ezetimibe; Fish Oils; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Niacin	2014
Beyond statins: assessing the alternatives. Some people can't tolerate statins, and others need additional medications to achieve healthy cholesterol levels. Harvard heart letter : from Harvard Medical School, 2014, Volume: 25, Issue:3 Topics: Anticholesteremic Agents; Azetidines; Bezafibrate; Cholesterol; Dietary Supplements; Exercise; Ezetimibe; Health Behavior; Health Promotion; Humans; Hyperlipidemias; Niacin	2014
Trends in the Use of Nonstatin Lipid-Lowering Therapy Among Patients With Coronary Heart Disease: A Retrospective Cohort Study in the Medicare Population 2007 to 2011. Journal of the American College of Cardiology, 2015, Oct-27, Volume: 66, Issue:17 Topics: Adult; Anticholesteremic Agents; Coronary Disease; Drug Utilization; Ezetimibe; Humans; Hyperlipidemias; Hypolipidemic Agents; Medicare; Niacin; Practice Patterns, Physicians'; Retrospective Studies; Risk Factors; United States	2015
Reducing CV risk in diabetes: An ADA update. The Journal of family practice, 2017, Volume: 66, Issue:5 Topics: Antihypertensive Agents; Aspirin; Benzhydryl Compounds; Cardiovascular Diseases; Contraindications; Creatinine; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Drug Chronotherapy; Ezetimibe; Fenofibrate; Glucosides; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Hypoglycemic Agents; Hypolipidemic Agents; Life Style; Liraglutide; Metformin; Niacin; PCSK9 Inhibitors; Platelet Aggregation Inhibitors; Risk Reduction Behavior; Thiazolidinediones	2017
Impact of conventional lipid-lowering therapy on circulating levels of PCSK9: protocol for a systematic review and meta-analysis of randomised controlled trials. BMJ open, 2022, 09-08, Volume: 12, Issue:9 Topics: Adult; Bile Acids and Salts; Ezetimibe; Fatty Acids; Fibric Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Meta-Analysis as Topic; Niacin; Proprotein Convertase 9; Proprotein Convertases; Review Literature as Topic; Subtilisin; Systematic Reviews as Topic	2022